Description
High blood pressure is a major risk factor for heart disease, yet treatment outcomes in real-world settings often fall short. A growing body of clinical trial evidence supports the use of amlodipine as a first-line antihypertensive agent due to its superior ability to reduce cardiovascular events such as stroke and myocardial infarction. Its unique mechanism not only ensures effective 24-hour blood pressure control but also reduces atherosclerosis progression and benefits patients with renal impairment. With strong safety and efficacy profiles, amlodipine improves outcomes and lowers hospitalization rates, making it a top choice in hypertension management.